July 2004 Br J Cardiol (Acute Interv Cardiol) 2004;11:AIC 35–AIC 37
Nicholas MK Robinson
The benefits of transradial coronary intervention (TRI)
over transfemoral (TFI) are becoming increasingly
recognised. In the United Kingdom, an increasing
number of interventions are being performed by the radial
approach and courses supporting this approach are now well
July 2004 Br J Cardiol (Acute Interv Cardiol) 2004;11:AIC 38–AIC 40
Arun Natarajan, Scott A Gall, Azfar Zaman
The success of the 3-hydroxy-3-methylglutaryl-coenzyme
A reductase inhibitors (statins) in ameliorating
atherothrombotic events is firmly established. Large
randomised controlled clinical trials have consistently (and
unequivocally) demonstrated a beneficial role in reducing
coronary events and total mortality in patients with advanced
coronary artery disease (CAD).
July 2004 Br J Cardiol 2004;11:261-2
Violet R Henry, Sharon Smart, Salma Akram, Katherine McGrath, Ian Wright, Sophie Blackman, Nicholas S Peters
Most treatments administered to patients act to relieve symptoms. But in the name of saving life,
having an implanted cardioverter defibrillator (ICD) leaves the patient prone to unpredictable episodes of
symptoms including collapse, and abrupt and explosive chest pain, of which the informed patient may live in
May 2004 Br J Cardiol 2004;11:175-8
Despite many attempts at reform, there has been a persistent
shortfall in the number of consultant cardiologists.
As long ago as 1985, the conservative recommendation
was made that each general hospital should have
at least one physician, practising general medicine but
having a special expertise and training in cardiology.
March 2004 Br J Cardiol 2004;11:93
Statins are currently provided at NHS expense for patients
with coronary heart disease (CHD), diabetes and those
whose coronary risk is greater than 3% per year.
March 2004 Br J Cardiol 2004;11:89-91
The difficulty in delivering a viable primary prevention
policy has been evident ever since the publication of
the National Service Framework for Coronary Heart
March 2004 Br J Cardiol (Acute Interv Cardiol) 2004;11:AIC 3–AIC 6
Jason Causer, Martyn Wood, Rodney H Stables
The measurement of biochemical markers of myocardial cell damage is a key component of modern cardiology practice. The use of these tests in the diagnosis of myocardial infarction (MI) has been routine for three decades, with the measurement of serum levels of creatine kinase (CK) and its myocardial band isofraction (CK-MB) emerging as the traditional standard in this respect.
March 2004 Br J Cardiol (Acute Interv Cardiol) 2004;11:AIC 7
In this issue of Acute and Interventional Cardiology there is a commissioned editorial about the release of cardiac enzymes after percutaneous coronary intervention (PCI). This remains a contentious area and attracts the views of two opposing schools of thought.
January 2004 Br J Cardiol 2004;11:22-3
The management of advanced heart failure when medical treatment alone is no longer sufficient was the focus of the 2003 British Society for Heart Failure (BSH) annual autumn meeting, held in Oxford on 28 November.
January 2004 Br J Cardiol 2004;11:16-21
BJCardio editorial team
A joint British Journal of Cardiology and H.E.A.R.T UK round table meeting held at the National Heart and Lung Institute, 18th November 2003.